SAB Adds To Executive Team With Industry Veteran

SAB Adds To Executive Team With Industry Veteran

November 12, 2019

SAB Biotherapeutics Raises $22M In Series A-2 Round

December 20, 2018
S.D. Equity Partners Makes $1M Investment In SAB

S.D. Equity Partners Makes $1M Investment In SAB

December 19, 2018
South Dakota Equity Partners Invests $1.05M In SAB Biotherapeutics

South Dakota Equity Partners Invests $1.05M In SAB Biotherapeutics

December 18, 2018
USD Discovery District Breaks Ground For First Building Project

USD Discovery District Breaks Ground For First Building Project

November 20, 2018
Ebola Successfully Neutralized By Latest Generation Polyclonal Immunotherapy

Ebola Successfully Neutralized By Latest Generation Polyclonal Immunotherapy

August 15, 2018
USD Discovery District Announces Anchor Tenants For Innovation Community

USD Discovery District Announces Anchor Tenants For Innovation Community

June 4, 2018
SAB Biotherapeutics Expands VAC Team

SAB Biotherapeutics Expands VAC Team

May 15, 2018
SAB Capra Awarded $225K From NIH To Broaden Novel Immunotherapy Platform

SAB Capra Awarded $225K From NIH To Broaden Novel Immunotherapy Platform

February 1, 2018
First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial

First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial

January 10, 2018
First-In-Human Trial Of New Immunotherapy Approach Shows Efficacy In Antibiotic Resistance

First-In-Human Trial Of New Immunotherapy Approach Shows Efficacy In Antibiotic Resistance

December 21, 2017
SAB Biotherapeutics Launches Utah-Based Subsidiary SAB Capra, LLC.

SAB Biotherapeutics Launches Utah-Based Subsidiary SAB Capra, LLC.

December 20, 2017